Jun 11, 2020
Celltrion’s Subsidiary Acquires Primary Care Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited
Mar 24, 2020
Biosimilars Market Worth $35.7 Billion by 2025 - Exclusive Report by MarketsandMarkets(TM)
Feb 10, 2020
US Biosimilars Market , Dosage, Price & Clinical Pipeline Outlook 2025
Jan 13, 2020
Growing Demand for Novel Drug Delivery Technologies that Allow Medication to Cross the Blood Brain Barrier
Dec 06, 2019
FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
Sep 30, 2019
Celltrion to Launch TemixysTM Double Combination Once-Daily Tablet for HIV Treatment in the U.S.
Sep 03, 2019
North America accounted for the largest share, accounting for approximately 30% of the global market, in 2017
Aug 30, 2019
Visiongain Report Offers Transformative Insights on the $8.6bn Inflammatory Bowel Diseases (IBD) Drug Market
Jul 18, 2019
Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China
Jul 16, 2019
Uptake of Biosimilars in the EU5 Blunts Share of AbbVie's Humira and Merck's Remicade in the Crohn's Disease and Ulcerative Colitis Markets, While a Black Cloud of Safety Concerns Still Follows Pfizer's Xeljanz
Jun 05, 2019
US Gastroenterologists Report VARSITY Trial Data and JAK Inhibitor Safety Concerns Will Impact Their Prescribing Behavior in Ulcerative Colitis, with Potential Implications for Crohn's Treatment
May 14, 2019
Global and China Monoclonal Antibody Market 2019-2025: Roche, Johnson & Johnson, Merck, Novartis, AbbVie and Amgen Dominate the Market
Apr 08, 2019
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
Mar 26, 2019
US Gastroenterologists Project Near-Term Growth of Takeda's Entyvio and Janssen's Stelara for the Treatment of Crohn's Disease, while Anticipated Increased Adoption of Pfizer's Xeljanz in Ulcerative Colitis is Likely to Interrupt Entyvio's Trajectory
Feb 25, 2019
AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting
Jan 25, 2019
Global Crohn's Disease Dynamic Market 2016-2018 & 2026: $13.8 Billion Market Will be Driven by Continued Strong Uptake of Johnson & Johnson's Interleukin 12/23 (IL-12/23) Inhibitor Stelara
Jan 14, 2019
Janssen's Stelara and Pfizer's Xeljanz Battle Takeda's Entyvio to Claim the Preferred Alternate Mechanism of Action Position in Inflammatory Bowel Disease Patients Who Are Being Switched from Their Current Treatment
Dec 17, 2018
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Nov 29, 2018
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications
Nov 01, 2018
Investigation Report on China's Infliximab (Johnson & Johnson) Market, 2018-2022